Consider IXINITY® for your active hemophilia B patients.

Peak factor levels when they need them.

Active people with hemophilia B who want effective bleed prevention and control and peak factor levels when they need them may benefit from treatment with IXINITY.1

Chris Kelly: College student and avid outdoorsman

Age: 20

Weight: 180 lb

Severity: Severe hemophilia B

Previous therapy: Plasma-derived product

Current therapy: IXINITY

Treatment regimen: Before hiking and on-demand

Considerations:

  • Developed an inhibitor as a child and switched to a plasma-derived product. Did not go back to a recombinant because of the plasma’s low-dose infusion.

Result:

  • IXINITY offers him a recombinant option with 0.98 IU/dL mean incremental recovery.1*

Description is not of an actual patient.

Jacob Cook: Devoted husband and active cyclist

Age: 31

Weight: 192 lb

Severity: Moderate hemophilia B

Previous therapy: Recombinant factor IX product

Current therapy: IXINITY

Treatment regimen: Infuses 2x/week based on his cycling schedule

Considerations:

  • Infuses before a big ride to reach peak factor level when his physical activity is greatest.

Result:

  • IXINITY fits Jacob’s active lifestyle by providing peak factor levels when he needs them.1*

Description is not of an actual patient.

Scott Wright: Scholarship swimmer

Age: 18

Weight: 173 lb

Severity: Moderate hemophilia B

Previous therapy: Recombinant factor IX product

Current therapy: IXINITY

Treatment regimen: Infuses before major training sessions

Considerations:

  • Will be independent at college and wants peak factor levels when he needs them and easy factor IX storage.

Result:

  • IXINITY works for Scott because of its 24-hour half-life and room-temperature storage.1*

Description is not of an actual patient.

Explore more about IXINITY

*The efficacy (n=68) and safety (n=77) of IXINITY have been evaluated in a prospective, open-label, uncontrolled, multicenter trial in which previously treated patients (PTPs) between 7 and 64 years of age received IXINITY in either a routine treatment or on-demand regimen.1

Reference: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Seattle, WA: Aptevo BioTherapeutics LLC; December 2018.